EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma

Daniel A Mohl iD, Simon Lagies iD, Kyra Zodel iD, Matthias Zumkeller, Asin Peighambari, Athina Ganner iD, Dietmar A Plattner, Elke Neumann-Haefelin, Mojca Adlesic, Ian J Frew iD, Bernd Kammerer

Cells · 2023

DOI: 10.3390/cells12081102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2023. Verfasst von Daniel A Mohl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Core Competence Metabolomics, Hilde-Mangold-Haus, University of Freiburg, 79104 Freiburg, Germany. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Deutsche Krebshilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clear cell renal cell carcinoma (ccRCC) accounts for ~75% of kidney cancers. The biallelic inactivation of the von Hippel–Lindau tumor suppressor gene (VHL) is the truncal driver mutation of most cases of ccRCC. Cancer cells are metabolically reprogrammed and excrete modified nucleosides in larger amounts due to their increased RNA turnover. Modified nucleosides occur in RNAs and cannot be recycled by salvage pathways. Their potential as biomarkers has been demonstrated for breast or pancreatic cancer. To assess their suitability as biomarkers in ccRCC, we used an established murine ccRCC model, harboring Vhl, Trp53 and Rb1 (VPR) knockouts. Cell culture media of this ccRCC model and primary murine proximal tubular epithelial cells (PECs) were investigated by HPLC coupled to triple-quadrupole mass spectrometry using multiple-reaction monitoring. VPR cell lines were significantly distinguishable from PEC cell lines and excreted higher amounts of modified nucleosides such as pseudouridine, 5-methylcytidine or 2′-O-methylcytidine. The method’s reliability was confirmed in serum-starved VPR cells. RNA-sequencing revealed the upregulation of specific enzymes responsible for the formation of those modified nucleosides in the ccRCC model. These enzymes included Nsun2, Nsun5, Pus1, Pus7, Naf1 and Fbl. In this study, we identified potential biomarkers for ccRCC for validation in clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansAnimalsMiceNucleosidesReproducibility of ResultsTranscriptomeVon Hippel-Lindau Tumor Suppressor ProteinRNA

Stichwörter der Autor:innen

HPLCRNA-seqbiomarker discoverybiomarkersccRCCkidney cancermass spectrometrymetabolomicsmodified nucleosidestranscriptomics

Substanzen

NucleosidesVon Hippel-Lindau Tumor Suppressor ProteinRNA

Autor:innen und Institutionen

  • Core Competence Metabolomics, Hilde-Mangold-Haus, University of Freiburg, 79104 Freiburg, Germany.
  • Institute of Organic Chemistry, University of Freiburg, 79104 Freiburg, Germany.
  • Institute of Medical Microbiology and Hygiene, Faculty of Medicine, Medical Center-University of Freiburg, 79104 Freiburg, Germany.
  • Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Centre-University of Freiburg, 79106 Freiburg, Germany.
  • Renal Division, Department of Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany.
  • German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

ORCID-Profile: Daniel A Mohl, Simon Lagies, Kyra Zodel, Athina Ganner, Ian J Frew

Förderung

  • Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
  • Deutsche Krebshilfe

Zitieren

APA

Mohl, D. A., Lagies, S., Zodel, K., Zumkeller, M., Peighambari, A., Ganner, A., Plattner, D. A., Neumann-Haefelin, E., Adlesic, M., Frew, I. J., & Kammerer, B. (2023). Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma. Cells. https://doi.org/10.3390/cells12081102

Vancouver

Mohl DA, Lagies S, Zodel K, Zumkeller M, Peighambari A, Ganner A, et al. Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma. Cells. 2023. doi:10.3390/cells12081102

BibTeX
@article{Mohl2023,
  author = {Mohl, Daniel A and Lagies, Simon and Zodel, Kyra and Zumkeller, Matthias and Peighambari, Asin and Ganner, Athina and Plattner, Dietmar A and Neumann-Haefelin, Elke and Adlesic, Mojca and Frew, Ian J and Kammerer, Bernd},
  title = {Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12081102}
}
Kostenlos starten →